Wipro Limited (WIT)
NYSE: WIT · Real-Time Price · USD
2.660
0.00 (0.00%)
At close: Aug 8, 2025, 4:00 PM
2.651
-0.010 (-0.36%)
After-hours: Aug 8, 2025, 7:54 PM EDT
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Intra-Cellular Therapies.
Price Target: $ (0.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Intra-Cellular Therapies is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Jan 2, 2025 |
| Wedbush | Wedbush | Sell Maintains $2 → $3 | Sell | Maintains | $2 → $3 | +12.78% | Jan 16, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Initiates $2.35 | Strong Sell | Initiates | $2.35 | -11.65% | Aug 22, 2023 |
| JP Morgan | JP Morgan | Sell Initiates $2.15 | Sell | Initiates | $2.15 | -19.17% | May 24, 2023 |
| Bernstein | Bernstein | Hold → Sell Downgrades $2.55 → $1.95 | Hold → Sell | Downgrades | $2.55 → $1.95 | -26.69% | Mar 22, 2023 |
Financial Forecast
Revenue This Year
929.33B
from 890.88B
Increased by 4.32%
Revenue Next Year
982.03B
from 929.33B
Increased by 5.67%
EPS This Year
13.29
from 12.52
Increased by 6.14%
EPS Next Year
14.19
from 13.29
Increased by 6.80%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 991.2B | 1.1T | 1.1T | ||
| Avg | 929.3B | 982.0B | 1.0T | ||
| Low | 852.5B | 871.7B | 918.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.3% | 15.4% | 14.8% | ||
| Avg | 4.3% | 5.7% | 5.8% | ||
| Low | -4.3% | -6.2% | -6.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.67 | 31.29 | 16.55 | ||
| Avg | 13.29 | 14.19 | 14.50 | ||
| Low | 11.46 | 11.68 | 12.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 129.0% | 135.5% | 16.6% | ||
| Avg | 6.1% | 6.8% | 2.1% | ||
| Low | -8.5% | -12.1% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.